Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Terminated 110 enrolled Tango Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Timeline

Start: 2022-03-23
Primary completion: 2025-12-30
Completion: 2025-12-30

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision - Business Decisions”

Publications

Briggs KJ, Cottrell KM, Tonini MR, Tsai A, Zhang M, Whittington DA, Zhang W, Lombardo SA, Yoda S, Wilker EW, Meier SR, Yu Y, Teng T, Huang A, Maxwell JP. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. Transl Oncol. 2025 Feb;52:102264. doi: 10.1016/j.tranon.2024.102264. Epub 2025 Jan 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TNG908	Unknown	—	Oral

Indications

No indication recorded.